1-2 of 2
Maysa Abu-Khalaf
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Overexpression of EpCAM in Uterine Serous Papillary Carcinoma: Implications for EpCAM-Specific Immunotherapy With Human Monoclonal Antibody Adecatumumab (MT201)

Free
Karim El-Sahwi, Stefania Bellone, Emiliano Cocco, Francesca Casagrande, Marta Bellone, Maysa Abu-Khalaf, Natalia Buza, Fattaneh A. Tavassoli, Pei Hui, Dominik Rüttinger, Dan-Arin Silasi, Masoud Azodi, Peter E. Schwartz, Thomas J. Rutherford, Sergio Pecorelli, Alessandro D. Santin
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (1): 57–66.
https://doi.org/10.1158/1535-7163.MCT-09-0675
Published: 12 January 2010
View articletitled, Overexpression of EpCAM in Uterine Serous Papillary Carcinoma: Implications for EpCAM-Specific Immunotherapy With Human Monoclonal Antibody Adecatumumab (MT201)
Open the PDF for Overexpression of EpCAM in Uterine Serous Papillary Carcinoma: Implications for EpCAM-Specific Immunotherapy With Human Monoclonal Antibody Adecatumumab (MT201) in another window
Journal Articles

A phase I study of the mTOR inhibitor sirolimus (rapamycin) in combination with nanoparticle albumin-bound paclitaxel (ABI-007, abraxane) in advanced solid cancers

Free
Maysa Abu-Khalaf, Scott Gettinger, Frederick Lansigan, Jeannie Klutenaar, Mary Beth Clark, Laurie Thomas, Indu Doddamane, William Kevin Kelly, David Rimm, Peter Schwartz, Lyndsay Harris
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): C151.
Published: 01 November 2007
View articletitled, A phase I study of the mTOR inhibitor sirolimus (rapamycin) in combination with nanoparticle albumin-bound paclitaxel (ABI-007, abraxane) in advanced solid cancers